Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Prediction: This Stock Could Double By 2031

TheMotleyFool

0 0

Prediction: This Stock Could Double By 2031Photo, wide shot, wide-angle lens, Gas company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/01083d82-021d-4573-8c40-0e836a0771d6.png

Exelixis (NASDAQ: EXEL) has been a solid stock to own over the past five years, with its shares climbing 101%, slightly beating out the S 500. The good news is that there is plenty of upside left for the biotech company. Over the next five years, the drugmaker could, once again, achieve 2-bagger status (that is, a stock that delivers 100% returns). Here is why.